We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis.
- Authors
Pardanani, Animesh; Tefferi, Ayalew; Masszi, Tamás; Mishchenko, Elena; Drummond, Mark; Jourdan, Eric; Vannucchi, Alessandro; Jurgutis, Mindaugas; Ribrag, Vincent; Rambaldi, Alessandro; Koh, Liang Piu; Rose, Shelonitda; Zhang, Jun; Harrison, Claire
- Abstract
Summary: Fedratinib, an oral Janus kinase‐2 (JAK2) inhibitor, reduces splenomegaly and improves symptom burden in patients with myelofibrosis. Regulatory approval of fedratinib 400‐mg daily was based on results of an updated analysis of the pivotal phase III, placebo‐controlled JAKARTA trial in patients with JAK‐inhibitor‐naïve myelofibrosis. At week 24, spleen volume response rate was 47% and symptom response rate was 40% with fedratinib 400 mg, versus 1% and 9% respectively, with placebo. Common adverse events were diarrhoea, nausea, anaemia, and vomiting. No Wernicke encephalopathy occurred in patients receiving fedratinib 400 mg/day. These updated data support use of first‐line fedratinib in patients with myelofibrosis.
- Subjects
JAKARTA (Indonesia); MYELOFIBROSIS; SPLEEN; REGULATORY approval; BRAIN diseases
- Publication
British Journal of Haematology, 2021, Vol 195, Issue 2, p244
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.17727